HALO - Halozyme Therapeutics - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US40637H1095

Enzymes, Devices, Injectables, Biologics, Therapies

Halozyme Therapeutics Inc. is a biopharma technology platform company that develops and commercializes innovative enzymes and devices to improve the delivery of injectable biologics and other therapeutic molecules. The company's proprietary technology is based on a patented recombinant human hyaluronidase enzyme (rHuPH20), which enables the delivery of a wide range of medications, including monoclonal antibodies, small molecules, and fluids, through subcutaneous injection.

The company's product portfolio includes Hylenex recombinant, which facilitates subcutaneous fluid administration for hydration and enhances the dispersion and absorption of other injected drugs. Additionally, Halozyme offers a range of medications for various indications, including HIV, multiple sclerosis, testosterone replacement therapy, and cancer treatment. These products include rilpivirine, cabotegravir, and N6LS BNAB for HIV treatment, ocrelizumab for multiple sclerosis, and XYOSTED for testosterone replacement therapy.

Halozyme also provides several medications for cancer treatment, including Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo for breast cancer, as well as Mabthera SC for chronic lymphocytic leukemia. Furthermore, the company offers HYQVIA for primary immunodeficiency disorders and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma.

In addition to its proprietary products, Halozyme also partners with other pharmaceutical companies to develop and commercialize new medications. The company's pipeline includes several promising candidates, such as Epinephrine Injection for allergic reactions, nivolumab+relatlimab and ANTI-TIM3 for solid tumors, and ARGX-117 for multifocal motor neuropathy.

Halozyme Therapeutics Inc. was founded in 1998 and is headquartered in San Diego, California. With a strong focus on innovation and collaboration, the company is committed to improving patient outcomes and advancing the field of biopharma technology.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for HALO - Halozyme Therapeutics  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for HALO - Halozyme Therapeutics  - Stock & Dividends

HALO Stock Overview

Market Cap in USD 7,507m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2004-03-16

HALO Stock Ratings

Growth 5y 72.6
Fundamental 89.6
Dividend 0.00
Rel. Performance vs Sector 0.27
Analysts 4.09/5
Fair Price Momentum 57.54 USD
Fair Price DCF 80.41 USD

HALO Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

HALO Growth Ratios

Growth 12m 46.03%
Growth Correlation 12m 87.7%
Growth Correlation 3m -3%
CAGR 5y 27.74%
CAGR/Mean DD 5y 1.52
Sharpe Ratio 12m 1.10
Alpha vs SP500 12m 10.15
Beta vs SP500 5y weekly 0.92
ValueRay RSI 9.31
Volatility GJR Garch 1y 35.78%
Price / SMA 50 -10.72%
Price / SMA 200 11.33%
Current Volume 1249.2k
Average Volume 20d 1570.5k

External Links for HALO Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of HALO stocks?
As of October 18, 2024, the stock is trading at USD 52.28 with a total of 1,249,223 shares traded.
Over the past week, the price has changed by +0.29%, over one month by -15.58%, over three months by -4.51% and over the past year by +48.69%.
What are the forecast for HALO stock price target?
According to ValueRays Forecast Model, HALO Halozyme Therapeutics will be worth about 63 in October 2025. The stock is currently trading at 52.28. This means that the stock has a potential upside of +20.49%.
Issuer Forecast Upside
Wallstreet Target Price 59.9 14.6
Analysts Target Price 51.9 -0.73
ValueRay Target Price 63 20.5